三维可吸收组织标记物置入与接受乳腺癌放疗患者瘤床体积减小相关
这项回顾性病例对照研究纳入2015年5月1日至2016年4月30日在罗德岛医院接受乳腺癌放疗的116例患者,其中42例置入三维可吸收标记物、74例未置入。置入组平均瘤床体积为27.5 cm³,未置入组为40.1 cm³,两组平均肿瘤切除体积相近(102.7 cm³ vs 103.2 cm³)。作者结论认为,在肿瘤切除体积相似的情况下,置入该标记物与统计学显著更小的瘤床体积相关(P = .001)。
要点
- 置入三维可吸收标记物组平均瘤床体积27.5 cm³,未置入组为40.1 cm³。
- 两组平均肿瘤切除体积相近:置入组102.7 cm³,未置入组103.2 cm³。
- 两组最佳拟合线斜率差异有统计学意义(P = .001),置入组瘤床体积更小。
核心结论
- 在肿瘤切除体积相似的情况下,置入三维可吸收标记物与统计学显著更小的瘤床体积相关。
研究设计与样本
- 回顾性病例对照研究,纳入2015年5月1日至2016年4月30日在罗德岛医院接受乳腺癌放疗的116例患者,按是否置入三维可吸收标记物分组。
主要发现
- 置入三维可吸收标记物组42例,未置入组74例。
- 置入组平均肿瘤切除体积为102.7 cm³,未置入组为103.2 cm³。
- 置入组平均瘤床体积为27.5 cm³,未置入组为40.1 cm³。
- 置入组瘤床体积标准误为23.739,未置入组为38.685。
- 两组最佳拟合线斜率的t检验差异有统计学意义(P = .001),置入三维可吸收标记物者瘤床体积更小。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: BioZorb® (Focal Therapeutics, Aliso Viejo, CA) is an implantable 3-dimensional bioabsorbable marker used for tumor bed volume (TBV) identification during postoperative radiation therapy (RT) planning. We aimed to calculate and compare RT TBVs between two cohorts managed with and without the device. METHODS AND MATERIALS: Data from patients with breast cancer who were treated at Rhode Island Hosptial, Providence RI between May 1, 2015 and April 30, 2016 were retrospectively reviewed and grouped based on 3-dimensional bioabsorbable marker placement. Pathology reports were used to calculate tumor excision volume (TEV) after breast conservation. Specifically, the three dimensions provided were multiplied to generate a cubic volume, defined as TEV. TBV was calculated using treatment volumes generated with Philips Pinnacle3 treatment planning software (Andover, MA). Linear regression analyses assessed the relationship between excised TEV and TBV. T tests compared the slopes of the best fit lines for plots of TEV versus TBV. RESULTS: In this retrospective case-control study, 116 patients undergoing breast RT were identified; of whom 42 received a 3-dimensional bioabsorbable marker and 74 did not. The mean TEVs were 102.7 cm3 with the device and 103.2 cm3 without the device, and the mean TBVs for the same groups were 27.5 cm3 and 40.1 cm3, respectively. The TBV standard errors for patients who did and did not receive 3-dimensional bioabsorbable markers were 23.739 and 38.685, respectively. The t tests found the slopes of the lines of best fit for these cohorts to be statistically significantly different (P = .001), with smaller TBVs achieved with 3-dimensional bioabsorbable marker placement. CONCLUSIONS: When comparing TBVs between patients contemporaneously treated with or without a 3-dimensional bioabsorbable marker, device placement was associated with statistically significantly smaller TBVs in the setting of similar TEVs.
引用
- Foster B, Sindhu K, Hepel J, et al. Three-Dimensional Bioabsorbable Tissue Marker Placement is Associated with Decreased Tumor Bed Volume Among Patients Receiving Radiation Therapy for Breast Cancer. Pract Radiat Oncol. 2018. PMID: 30268431. doi:10.1016/j.prro.2018.09.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。